# Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

> **NCT06796361** · PHASE1 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 16 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ketanserin 40mg plus Psilocybin 40mg
- **DRUG:** 40mg Psilocybin
- **DRUG:** 20mg Psilocybin
- **DRUG:** 10mg Psilocybin
- **DRUG:** 5mg Psilocybin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06796361
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796361, "Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06796361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*